title: Retrospective analysis of patients with primary fallopian tube carcinoma treated at the University of Louisville.
abstract: Medical records of patients diagnosed with primary fallopian tube carcinoma between 1979 and 1989 were reviewed. Twenty-six patients were eligible; 8 patients were excluded after pathologic review, leaving 18 patients included in the study for this analysis. The median and mean age were 61 and 59 years, respectively, with a range of 39-80 years. There were three Stage I, five Stage II, seven Stage III, and three Stage IV patients. The most common presenting symptoms were abdominal/pelvic pain, abdominal distension, and vaginal discharge/bleeding. The primary site of the lesion was determined to be the right tube in 44% of the cases, the left tube in 39% of the patients, bilateral lesions in 11% of the patients, and indeterminate in 6%. Histologic grade was poorly differentiated (Grade III) in 13 patients, moderately differentiated (Grade II) in 4 patients, and well differentiated (Grade I) in one. No patient was correctly diagnosed preoperatively. Survival at 5 years of the entire group was 35% with a 3 year minimum followup. Corresponding disease free survival was 30%. Mean and median survival times were 74 and 37 months, respectively. The range of survival times was from 1 to 120 months. All Stage I patients, 80% (4/5) of Stage II, and 29% (2/7) of Stage III patients are alive without disease. None (0/3) of the Stage IV patients are alive. Treatment regimens consisted of intraperitoneal P-32, external beam radiotherapy, and/or chemotherapy. Radiotherapy was associated with a low incidence of treatment-related complications, the majority being gastrointestinal related. There was one chemotherapy-related death. These patients and their treatment outcomes add to the data base of numerous previous reports on fallopian tube carcinoma. Stage I and II patients fared excellently with primary surgical and adjuvant therapy. While the prognosis of Stage III and IV patients is much worse, significant levels of long term survival can be achieved with aggressive treatment.
authors.affiliation: Department of Radiation Oncology, James Graham Brown Cancer Center, University of Louisville School of Medicine, Ky., USA.
authors.forename: D F
authors.initials: DF
authors.lastname: Butler
authors.forename: M E
authors.initials: ME
authors.lastname: Bolton
authors.forename: W J
authors.initials: WJ
authors.lastname: Spanos
authors.forename: T G
authors.initials: TG
authors.lastname: Day
authors.forename: K J
authors.initials: KJ
authors.lastname: Paris
authors.forename: B O
authors.initials: BO
authors.lastname: Jose
authors.forename: D M
authors.initials: DM
authors.lastname: Ackerman
authors.forename: M S
authors.initials: MS
authors.lastname: Cornett
authors.forename: R D
authors.initials: RD
authors.lastname: Lindberg
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003131:Combined Modality Therapy; D005185:Fallopian Tube Neoplasms / Q000453:epidemiology / Q000628:therapy*; D005260:Female; D006801:Humans; D007629:Kentucky / Q000453:epidemiology; D008875:Middle Aged; D009367:Neoplasm Staging; D012042:Registries / Q000706:statistics & numerical data; D012189:Retrospective Studies; D016019:Survival Analysis